Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Taysha Gene Therapies, Inc. - Common Stock (NQ:TSHA)

5.840 -0.020 (-0.34%)
Streaming Delayed Price Updated: 12:21 PM EDT, Aug 3, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 724,602
Open 5.890
Bid (Size) 5.830 (800)
Ask (Size) 5.840 (1,700)
Prev. Close 5.860
Today's Range 5.630 - 5.960
52wk Range 2.540 - 7.300
Shares Outstanding 64,465,037
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Taysha Gene Therapies and Catalent Expand Strategic Partnership to Include Future Commercial Manufacturing Support of TSHA-102 Gene Therapy for Rett Syndrome
From Taysha Gene Therapies, Inc.
Via GlobeNewswire
News headline image
Taysha's R&D Chief Sold $1.2 Million in Stock After a 149% Run ↗
Nagendran Sukumar executed the sale under a pre-established Rule 10b5-1 trading plan, retaining 936,410 shares worth $5.94 million. 
Via The Motley Fool
Topics Regulatory Compliance

Performance

YTD
+11.2%
+11.2%
1 Month
-8.5%
-8.5%
3 Month
-12.0%
-12.0%
6 Month
+25.3%
+25.3%
1 Year
+115.5%
+115.5%

More News

Read More
News headline image
Taysha Gene Therapies Announces Multiple Presentations Highlighting its TSHA-102 Clinical Program at the 2026 IRSF Rett Syndrome Scientific Meeting
From Taysha Gene Therapies, Inc.
Via GlobeNewswire
Taysha Gene Therapies (NASDAQ:TSHA) Reports Q1 2026 Miss, Reaffirms FDA Alignment on TSHA-102 Approval Path ↗
Via Chartmill
Taysha Gene Therapies Inc (NASDAQ:TSHA) Reports Q4 2025 Revenue Beat and Key Rett Syndrome Program Updates ↗
Via Chartmill
News headline image
Earnings Scheduled For November 4, 2025 ↗
Via Benzinga
News headline image
Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
From Taysha Gene Therapies, Inc.
Via GlobeNewswire
News headline image
Taysha Gene Therapies Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
From Taysha Gene Therapies, Inc.
Via GlobeNewswire
News headline image
Taysha Gene Therapies Announces Completion of Dosing in REVEAL Pivotal Trial and Reports Longer-Term Clinical Data from Part A of REVEAL Phase 1/2 Trials Evaluating TSHA-102 for Rett Syndrome
From Taysha Gene Therapies, Inc.
Via GlobeNewswire
News headline image
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Taysha Gene Therapies, Inc.
Via GlobeNewswire
News headline image
Taysha (TSHA) Q1 2026 Earnings Transcript ↗
Via The Motley Fool
News headline image
Taysha Gene Therapies Reports First Quarter 2026 Financial Results and Provides Corporate Update
From Taysha Gene Therapies, Inc.
Via GlobeNewswire
News headline image
Taysha Gene Therapies to Release First Quarter 2026 Financial Results and Host Conference Call and Webcast on May 6
From Taysha Gene Therapies, Inc.
Via GlobeNewswire
News headline image
Taysha Gene Therapies to Present New Preclinical Data Supporting Construct Design of TSHA-102 for Rett Syndrome at the ASGCT 2026 Annual Meeting
From Taysha Gene Therapies, Inc.
Via GlobeNewswire
News headline image
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Taysha Gene Therapies, Inc.
Via GlobeNewswire
News headline image
Ultragenyx Vaults Toward Commercialization as FDA Accepts Landmark Gene Therapy BLA
Via MarketMinute
Topics Intellectual Property Lawsuit
News headline image
Structure Therapeutics Slides 28% This Year as $6 Million Stake Emerges ↗
Via The Motley Fool
News headline image
Taysha (TSHA) Q4 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
Taysha Gene Therapies Reports Full-Year 2025 Financial Results and Provides Corporate Update
From Taysha Gene Therapies, Inc.
Via GlobeNewswire
News headline image
Taysha Gene Therapies to Release Full-Year 2025 Financial Results and Host Conference Call and Webcast on March 19
From Taysha Gene Therapies, Inc.
Via GlobeNewswire
News headline image
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Taysha Gene Therapies, Inc.
Via GlobeNewswire
News headline image
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Taysha Gene Therapies, Inc.
Via GlobeNewswire
News headline image
Taysha Gene Therapies Inc (NASDAQ:TSHA) Stock Slumps on Q3 Revenue Miss Despite Key Regulatory Win for TSHA-102 ↗
Via Chartmill
News headline image
Olema Pharmaceuticals, Exelixis, Genmab And Other Big Stocks Moving Lower In Monday's Pre-Market Session ↗
Via Benzinga
News headline image
Why Is Taysha Gene Therapies Stock Falling Friday? ↗
Via Benzinga

Frequently Asked Questions

Is Taysha Gene Therapies, Inc. - Common Stock publicly traded?
Yes, Taysha Gene Therapies, Inc. - Common Stock is publicly traded.
What exchange does Taysha Gene Therapies, Inc. - Common Stock trade on?
Taysha Gene Therapies, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Taysha Gene Therapies, Inc. - Common Stock?
The ticker symbol for Taysha Gene Therapies, Inc. - Common Stock is TSHA on the Nasdaq Stock Market
What is the current price of Taysha Gene Therapies, Inc. - Common Stock?
The current price of Taysha Gene Therapies, Inc. - Common Stock is 5.840
When was Taysha Gene Therapies, Inc. - Common Stock last traded?
The last trade of Taysha Gene Therapies, Inc. - Common Stock was at 08/03/26 12:21 PM ET
What is the market capitalization of Taysha Gene Therapies, Inc. - Common Stock?
The market capitalization of Taysha Gene Therapies, Inc. - Common Stock is 376.48M
How many shares of Taysha Gene Therapies, Inc. - Common Stock are outstanding?
Taysha Gene Therapies, Inc. - Common Stock has 376M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.